In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ptc Therapeutics Inc. (NASDAQ:PTCT) reported that Complete Pharma Holdings Ii, Llc. has picked up 6,683,598 of common stock as of 2017-04-27.
The acquisition brings the aggregate amount owned by Complete Pharma Holdings Ii, Llc. to a total of 6,683,598 representing less than 16.2% stake in the company.
For those not familiar with the company, PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered small-molecule compound for the treatment of patients with genetic disorders due to a nonsense mutation. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF). PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. RG7916 is an investigational oral therapeutic, which is in two clinical studies: SUNFISH, a trial in childhood onset (Type II/III) spinal muscular atrophy (SMA) patients, and FIREFISH, a trial in infant onset (Type I) SMA patients.
A glance at Ptc Therapeutics Inc. (NASDAQ:PTCT)’s key stats reveals a current market capitalization of 420.63 Million based on 34.56 Million shares outstanding and a price at last close of $12.01 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-03-03, Rothera picked up 2,000 at a purchase price of $6.23. This brings their total holding to 5,125 as of the date of the filing.
On the sell side, the most recent transaction saw Almstead unload 78 shares at a sale price of $11.82. This brings their total holding to 2,687.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ptc Therapeutics Inc. (NASDAQ:PTCT) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
